Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter J Houghton

Showing results (1-10 of 325) with videos related to

Pageof 33
Sort By:
Translational Pediatrics|April 9, 2024
Advances in the treatment of BRAF-mutant low-grade glioma with MAPK inhibitorsPeter J Houghton
Expert Review of Anticancer Therapy|October 8, 2013
New insights into drug development for pediatric solid tumors: what preclinical data justify clinical trials in pediatric cancer?Peter J Houghton
Journal of Chromatography. A|September 11, 2002
Chromatography of the chromone and flavonoid alkaloidsPeter J Houghton
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 25, 2010
EverolimusPeter J Houghton
Pediatric Blood & Cancer|November 8, 2008
How do we identify novel treatment for childhood cancer?Peter J Houghton
Journal of Ethnopharmacology|July 22, 2008
Antibacterial, antioxidant and fibroblast growth stimulation of aqueous extracts of Ficus asperifolia Miq. and Gossypium arboreum L., wound-healing plants of GhanaKofi Annan, Peter J Houghton
Targeted Oncology|April 19, 2011
Regulation of mammalian target of rapamycin complex 1 (mTORC1) by hypoxia: causes and consequencesHakan Cam, Peter J Houghton
Current Opinion in Investigational Drugs (London, England : 2000)|May 22, 2002
Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinicShile Huang, Peter J Houghton
Proceedings of the National Academy of Sciences of the United States of America|July 3, 2013
The mTOR pathway negatively controls ATM by up-regulating miRNAsChangxian Shen, Peter J Houghton
Oncotarget|June 11, 2014
Targeting FANCD2 for therapy sensitizationChangxian Shen, Peter J Houghton
Pageof 33

Showing results (1-10 of 325) with videos related to

Sort By:
Pageof 33
Translational Pediatrics|April 9, 2024
Advances in the treatment of BRAF-mutant low-grade glioma with MAPK inhibitorsPeter J Houghton
Expert Review of Anticancer Therapy|October 8, 2013
New insights into drug development for pediatric solid tumors: what preclinical data justify clinical trials in pediatric cancer?Peter J Houghton
Journal of Chromatography. A|September 11, 2002
Chromatography of the chromone and flavonoid alkaloidsPeter J Houghton
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 25, 2010
EverolimusPeter J Houghton
Pediatric Blood & Cancer|November 8, 2008
How do we identify novel treatment for childhood cancer?Peter J Houghton
Journal of Ethnopharmacology|July 22, 2008
Antibacterial, antioxidant and fibroblast growth stimulation of aqueous extracts of Ficus asperifolia Miq. and Gossypium arboreum L., wound-healing plants of GhanaKofi Annan, Peter J Houghton
Targeted Oncology|April 19, 2011
Regulation of mammalian target of rapamycin complex 1 (mTORC1) by hypoxia: causes and consequencesHakan Cam, Peter J Houghton
Current Opinion in Investigational Drugs (London, England : 2000)|May 22, 2002
Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinicShile Huang, Peter J Houghton
Proceedings of the National Academy of Sciences of the United States of America|July 3, 2013
The mTOR pathway negatively controls ATM by up-regulating miRNAsChangxian Shen, Peter J Houghton
Oncotarget|June 11, 2014
Targeting FANCD2 for therapy sensitizationChangxian Shen, Peter J Houghton
Pageof 33